回复5楼 薛傳恽
回复5楼 薛傳恽:
We investigate the potential to reposition clinically relevant and therapeutically tolerated FDA-approved drugs to treat neurodegenerative diseases. We found that two anti-cancer drugs, including the TKI nilotinib (Tasigna) and bosutinib (Bosulif) cross the blood barrier, induce autophagic protein clearance and modulate brain and peripheral immunity in pre-clinical models of AD, PD, MND-FTD and other related diseases.
他说bosutinib (Bosulif) 也会起效,你要不要换个来试